Meta AnalysisID 6185
6种口服中成药治疗冠心病血脂异常的贝叶斯网状Meta分析
CRD42019136670
What is the difference of therapeutic effect of 6 kinds of oral Chinese patent medicines on patients with Dyslipidemia in Coronary Heart Disease?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6185
- Evidence Id
- 14743
- Core Evidence Id
- 14743
- Source Meta Analysis Id
- 6164
- Herb2 Meta Analysis Id
- HBMA006164
- Crd Id
- CRD42019136670
- Title
- Bayesian network meta-analysis of 6 kinds of oral Chinese patent medicines for dyslipidemia in coronary heart disease patients
- Review Question
- What is the difference of therapeutic effect of 6 kinds of oral Chinese patent medicines on patients with Dyslipidemia in Coronary Heart Disease?
- Study Type Included
- We will include randomised trials to assess the beneficial effects and side effects of the treatments for Dyslipidemia in Coronary Heart Disease.
- Condition Being Studied
- Efficacy and safety of oral Chinese patent medicine in the treatment of Dyslipidemia in Coronary Heart Disease Patients
- Participant
- Inclusion: Patients with coronary heart disease and Low density lipoprotein cholesterol (LDL-C) > 0.18mmol/L (70mg/dl). Exclusion: Failure to meet inclusion criteria.
- Animal
- Human Disease Modelled
- Intervention
- The 6 species of Chinese patent medicines of Xinmaitong Capsule、Xinyuan capsule、Jiangzhi Tongluo Soft Capsule、Pushen Capsule、Hedan Tablet and Yangxinshi Tablet Therapy for Dyslipidemia in Coronary Heart Disease Patients.
- Comparator Control
- Conventional Western Medicine Therapy for Dyslipidemia in Coronary Heart Disease Patients.
- Main Outcome
- total cholesterol（TC)、triglyceride（TG)、Low density lipoprotein cholesterol（LDL—C） and effective rate of clinical effect of coronary heart disease. Measures of effect At least three months after the treatment.
- Outcome Measure
- Additional Outcome
- electrocardiogram and High density lipoprotein cholesterol（HDL—C） Measures of effect At least three months after the treatment.
- Study Method
- Network meta-analysis, Systematic review
- Keyword
- Bayes Theorem; Coronary Disease; Dyslipidemias; Humans; Network Meta-Analysis; Nonprescription Drugs
- Contact
- Zhao Yang [email protected]
- Organisational Affiliation
- Funding Source
- Self financing
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- Chinese-Simplified, English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2019-05-24
- Registration Date
- 2019-07-22
- Anticipated Start Date
- 2019-05-25
- Anticipated Completion Date
- 2019-07-25
- Title Cn
- 6种口服中成药治疗冠心病血脂异常的贝叶斯网状Meta分析
- Title En
- Bayesian network meta-analysis of 6 kinds of oral Chinese patent medicines for dyslipidemia in coronary heart disease patients
- Bilingual Status
- complete